N/A
Completed N=765
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
Source: ClinicalTrials.gov NCT02612077 ↗Enrolled (actual)
765
Serious AEs
9.7%
Results posted
Mar 2016
Primary outcomePrimary: Progression-free Survival — 10.4; 8.5; 6.3 Months
Summary
This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival |
10.4; 8.5; 6.3 | — |
| SECONDARY Overall Survival |
25.3; 19.1; 14.9 | — |
| SECONDARY Quality of Life - Global Health Status |
67; 67; 67; 67 | — |
Eligibility Criteria
Inclusion Criteria
- Having colon or rectal metastatic adenocarcinoma, for which the physician decided during the inclusion visit to start a treatment with bevacizumab combined with a 1st, 2nd or 3rd line chemotherapy
- Having received oral and written information about the survey and not objecting to having his/her data computerized
Exclusion Criteria
- Participating in a clinical trial assessing an anticancer treatment
Data sourced from ClinicalTrials.gov (NCT02612077). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.